<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594293</url>
  </required_header>
  <id_info>
    <org_study_id>CEASE</org_study_id>
    <nct_id>NCT02594293</nct_id>
  </id_info>
  <brief_title>Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy</brief_title>
  <official_title>A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether Peg-IFN alfa-2a can reduce the recurrence rate of hepatitis B in
      96 weeks after nucleoside analogue (NUC) withdrawal.

      The HBV HBeAg-Negative patients who received NUC anti-virus treatment for 2.5 years and
      reached stopping rule in 《Chinese chronic hepatitis B prevention and treatment
      guidelines》(2010) were randomly assigned into three groups: One group discontinue the NUC
      treatment and follow up for 96 weeks,One discontinue the NUC treatment ,receive Peg-IFN
      alfa-2a 180 μg by week for 24 weeks and follow up for 72 weeks,The other discontinue the NUC
      treatment ,receive Peg-IFN alfa-2a 180 μg by week for 48 weeks and follow up for 48 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NUC is a potent inhibitor of hepatitis B viral(HBV) replication, but long-term therapy may be
      required. Therefore, NUC resistance is an important clinical risk resulting from long-term
      therapy in chronic hepatitis B (CHB) management. Discontinuation of NUC is a feasible
      strategy to reduce resistance. However, the high rate of relapse after cessation of NUC
      treatment in CHB patients remains a big problem. NUC treatment of how to safely stop drug
      needs to be solved.

      Peg-IFN can clear HBV by direct anti-viral and immune regulation mechanisms including
      enhancing natural killer cell response, increased cluster of differentiation 8(CD8 +) T
      lymphocytes and other mechanisms to restore and enhance the immune response in patients with
      CHB. Response to PEG-IFN is frequently sustained after a finite treatment course due to its
      immune modulating capacity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who relapse</measure>
    <time_frame>96 weeks</time_frame>
    <description>The total number of relapse (HBV DNA&gt;2000 IU/ml on 2 separate occasions 1 months apart) during the research period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who relapse</measure>
    <time_frame>48 weeks</time_frame>
    <description>The total number of relapse (HBV DNA&gt;2000 IU/ml on 2 separate occasions 1 months apart) during the research period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who achieve HBsAg seroconversion</measure>
    <time_frame>At the point of discontinuation of PegIFN therapy</time_frame>
    <description>To investigate whether Peg-IFN alfa-2a can improve the HBsAg seroconversion in CHB patients at the point of discontinuation of PegIFN therapy compared to the control group ,which will be measured by the number of participants who achieve HBsAg seroconversion. Pegasys 24 weeks Group:24 weeks and Pegasys 48 weeks Group:48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who achieve HBsAg seroconversion</measure>
    <time_frame>24,48,72 weeks post-discontinuation of PegIFN therapy</time_frame>
    <description>To investigate whether Peg-IFN alfa-2a can improve the HBsAg seroconversion in CHB patients at 24,48 or 72 weeks post-discontinuation of PegIFN therapy compared to the control group ,which will be measured by the number of participants who achieve HBsAg seroconversion. Pegasys 24 weeks Group:48,72,96 weeks and Pegasys 48 weeks Group:72,96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg changes from Baseline</measure>
    <time_frame>12,24 and 48 weeks</time_frame>
    <description>Pegasys 24 weeks Group:12,24 weeks and Pegasys 48 weeks Group:12,24,48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of other markers for recurrence after NUC withdrawal</measure>
    <time_frame>48 weeks and 96 weeks</time_frame>
    <description>To investigate whether the other markers including HBcAb quantification and so on can predict the recurrence of hepatitis B.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Controlled Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Discontinue the NA treatment and follow up for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegasys 24 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 24 weeks and follow up for 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegasys 48 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 48 weeks and follow up for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIFN alfa-2a</intervention_name>
    <description>180 μg/ 0.5 ml ,hypodermic injection once a week</description>
    <arm_group_label>Pegasys 24 weeks</arm_group_label>
    <arm_group_label>Pegasys 48 weeks</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HBeAg-Negative Chronic Hepatitis B
             Patients：HBsAg-Positive,HBsAb-Negative,HBeAg-Negative,HBeAb-Positive during screening
             period and before NA treatment

          2. NUC monotherapy (including adefovir and entecavir) for more than 2.5 years,and reached
             stopping rule in 《Chinese chronic hepatitis B prevention and treatment
             guidelines》(2010):the patients who achieved undetectable HBV DNA (&lt;300 copies/mL) with
             normal alanine aminotransferase (ALT) and the consolidation therapy reached 1.5 years
             ,total course of the treatment reached 2.5 years can stop NUC therapy

          3. Willing to stop the drug, and signed a written informed consent

        Exclusion Criteria:

          1. HBsAb positive in screening period

          2. Compensated or Decompensated liver cirrhosis:with history of cirrhosis before NUC
             treatment or Child-Pugh score ≥ 5 or Complications of liver cirrhosis such as ascites,
             hepatic encephalopathy, esophageal gastric varices bleeding

          3. Hypersensitivity to interferon(IFN) or its active substance, and ineligible to IFN

          4. A history of immunoregulation drug therapy within one year before entry including IFN
             and so on.

          5. Coinfection with HAV、HCV、HDV、HEV 、HIV or with Other chronic liver diseases such as
             Alcoholic Liver Disease,Inherited Metabolic Liver Disease,Drug induced Liver Disease
             and nonalcoholic fatty liver

          6. Autoimmune disease including Autoimmune hepatitis and Psoriasis and so on.

          7. Hepatocellular carcinoma(HCC) or alpha feto protein(AFP) levels more than 100 ng/ml
             and Hepatic malignant potential of Imaging examination or AFP levels more than 100
             ng/ml for 3 months

          8. A neutrophil count of less than 1500 per cubic millimeter or a platelet count of less
             than 90,000 per cubic millimeter

          9. A serum creatinine level that was more than 1.5 times the upper limit of the normal
             range

         10. With other malignant tumors(exclude the cured ones)

         11. Severe organ dysfunction

         12. With severe psychiatric condition or nervous disease such as epilepsy, depression,
             mania, epilepsy, schizophrenia and so on

         13. Uncontrolled diabetes, hypertension or thyroid disease

         14. Pregnant women and lactating women or patients with pregnancy plans and not willing to
             use contraception during the study period

         15. Participate in other clinical studies at the same time

         16. Patients unsuitable for the research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiming Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiming Zhang, M.D.</last_name>
    <email>jmzhang2006@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wuhan Seventh People's Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Youqin Yan</last_name>
    </contact>
    <investigator>
      <last_name>Youqin Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changzhou Third People's Hospital</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Longgen Liu</last_name>
    </contact>
    <investigator>
      <last_name>Longgen Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yida Yang</last_name>
    </contact>
    <investigator>
      <last_name>Yida Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Jiangsu Province</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jun Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantong Third People's Hospital</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Songping Huang</last_name>
    </contact>
    <investigator>
      <last_name>Songping Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suzhou Fifth People's Hospital</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuanwu Zhu</last_name>
    </contact>
    <investigator>
      <last_name>Chuanwu Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weifeng Zhao</last_name>
    </contact>
    <investigator>
      <last_name>Weifeng Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taicang People's Hospital</name>
      <address>
        <city>Taicang</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yonglan Pu</last_name>
    </contact>
    <investigator>
      <last_name>Yonglan Pu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuxi Infectious Disease Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihua Huang</last_name>
    </contact>
    <contact_backup>
      <last_name>Huan</last_name>
    </contact_backup>
    <investigator>
      <last_name>Lihua Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Xuzhou Medical College</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiucheng Pan</last_name>
    </contact>
    <investigator>
      <last_name>Xiucheng Pan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wanhua Ren</last_name>
    </contact>
    <investigator>
      <last_name>Wanhua Ren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingxing Li</last_name>
    </contact>
    <investigator>
      <last_name>Qingxing Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital Affiliated to Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chengzhong Li</last_name>
    </contact>
    <investigator>
      <last_name>Chengzhong Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiming Zhang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jiming zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliate to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinxin Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Xinxin Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiefei Wang</last_name>
    </contact>
    <investigator>
      <last_name>Jiefei Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Third People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Xu</last_name>
    </contact>
    <investigator>
      <last_name>Jie Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shuguang Hospital Affiliate to Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yueqiu Gao</last_name>
    </contact>
    <investigator>
      <last_name>Yueqiu Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Infectious Disease Hospital of Shanghai Huangpu Distric</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hailin Liang</last_name>
    </contact>
    <investigator>
      <last_name>Hailin Liang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004 Mar 11;350(11):1118-29. Review. Erratum in: N Engl J Med. 2004 Sep 16;351(12):351.</citation>
    <PMID>15014185</PMID>
  </results_reference>
  <results_reference>
    <citation>Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009 Nov 5;27(47):6550-7. doi: 10.1016/j.vaccine.2009.08.048. Epub 2009 Sep 1.</citation>
    <PMID>19729084</PMID>
  </results_reference>
  <results_reference>
    <citation>Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis. 2009 Jul 1;200(1):39-47. doi: 10.1086/599332.</citation>
    <PMID>19469708</PMID>
  </results_reference>
  <results_reference>
    <citation>Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl). 2009 Jan 5;122(1):3-4.</citation>
    <PMID>19187608</PMID>
  </results_reference>
  <results_reference>
    <citation>European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012 Jul;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. Epub 2012 Mar 20. Erratum in: J Hepatol. 2013 Jan;58(1):201. Janssen, Harry [corrected to Janssen, Harry L A].</citation>
    <PMID>22436845</PMID>
  </results_reference>
  <results_reference>
    <citation>Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009 Sep;50(3):661-2. doi: 10.1002/hep.23190.</citation>
    <PMID>19714720</PMID>
  </results_reference>
  <results_reference>
    <citation>Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008 Sep;2(3):263-83. doi: 10.1007/s12072-008-9080-3. Epub 2008 May 10.</citation>
    <PMID>19669255</PMID>
  </results_reference>
  <results_reference>
    <citation>中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版).中华内科杂志,2011;50(2):168-179</citation>
  </results_reference>
  <results_reference>
    <citation>Kim YJ, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, Cho SW. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients. Clin Mol Hepatol. 2013 Sep;19(3):300-4. doi: 10.3350/cmh.2013.19.3.300. Epub 2013 Sep 30.</citation>
    <PMID>24133668</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu F, Wang L, Li XY, Liu YD, Wang JB, Zhang ZH, Wang YZ. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol. 2011 Mar;26(3):456-60. doi: 10.1111/j.1440-1746.2010.06492.x.</citation>
    <PMID>21332542</PMID>
  </results_reference>
  <results_reference>
    <citation>Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, Yuen MF, Chan HL. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut. 2015 Apr;64(4):667-72. doi: 10.1136/gutjnl-2014-307237. Epub 2014 May 15.</citation>
    <PMID>24833635</PMID>
  </results_reference>
  <results_reference>
    <citation>Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology. 2013 Dec;58(6):1888-96. doi: 10.1002/hep.26549. Epub 2013 Oct 17.</citation>
    <PMID>23744454</PMID>
  </results_reference>
  <results_reference>
    <citation>Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, Andreone P, Maini MK. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol. 2013 Feb;58(2):225-33. doi: 10.1016/j.jhep.2012.09.029. Epub 2012 Oct 6.</citation>
    <PMID>23046671</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen J, Wang Y, Wu XJ, Li J, Hou FQ, Wang GQ. Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B. World J Gastroenterol. 2010 Dec 28;16(48):6145-50.</citation>
    <PMID>21182232</PMID>
  </results_reference>
  <results_reference>
    <citation>Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013 Mar;7(1):88-97. doi: 10.1007/s12072-012-9343-x. Epub 2012 Mar 23.</citation>
    <PMID>23518903</PMID>
  </results_reference>
  <results_reference>
    <citation>Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014 Oct;61(4):777-84. doi: 10.1016/j.jhep.2014.05.044. Epub 2014 Jun 7.</citation>
    <PMID>24915612</PMID>
  </results_reference>
  <results_reference>
    <citation>Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol. 2013 Dec;58(4):713-7. doi: 10.1016/j.jcv.2013.09.020. Epub 2013 Sep 29.</citation>
    <PMID>24183313</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Jiming Zhang</investigator_full_name>
    <investigator_title>chief physician,professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

